Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 2152-2157, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hiramatsu, M.
Right arrow Articles by Kanno, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hiramatsu, M.
Right arrow Articles by Kanno, T.
Related Collections
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1998;44:2152-2157.)
© 1998 American Association for Clinical Chemistry, Inc.

Lipids and Lipoproteins

Enzyme immunoassay of urinary mevalonic acid and its clinical application

Makoto Hiramatsu1,a, Akio Hayashi1, Hideki Hidaka2, Hirotsugu Ueshima3, and Takashi Kanno4

1 Minase Research Institute, Ono Pharmaceutical Company Ltd., 3-1-1 Sakurai, Shimamoto-cho, Osaka 618-8585, Japan.

2 Third Department of Medicine, Siga University of Medical Science, Otsu 520-2152, Japan.

3 Department of Health Science, Siga University of Medical Science, Otsu 520-2152, Japan.

4 Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3124, Japan.
a Author for correspondence. Fax 8175-962-9314.

We have developed an enzyme immunoassay for mevalonic acid (MVA), using a specific monoclonal antibody. The intra- and interassay coefficients of variation calculated on two urine samples were 3.3% and 3.4%, respectively, in the intraassay precision test and 3.5% and 6.9% in the interassay evaluation. Pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, was administered to nine healthy men, and in all cases, their MVA excretion rates then decreased. The more MVA that was excreted in the urine before the pravastatin administration, the greater a reduction of MVA excretion was observed. The daily MVA excretions in healthy men (n = 120) and women (n = 105) were 2.32 µmol/day (SD, 0.82 µmol/day) and 1.85 µmol/day (SD, 0.47 µmol/day), respectively. In streptozotocin-induced diabetic rats (n = 14), the plasma cholesterol concentrations and MVA excretion rates were increased, and a positive correlation was observed between the plasma cholesterol and the urinary MVA concentrations.




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Lipid Res.Home page
G. S. Saini, T. A. Wani, A. Gautam, B. Varshney, T. Ahmed, K. S. Rajan, K. K. Pillai, and J. K. Paliwal
Validation of the LC-MS/MS method for the quantification of mevalonic acid in human plasma and determination of the matrix effect
J. Lipid Res., October 1, 2006; 47(10): 2340 - 2345.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.